



04/10/98

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

SUITE 600

1100 NEW YORK AVENUE, N.W.

WASHINGTON, D.C. 20005-3934

(202) 371-2600

FACSIMILE (202) 371-2540 (202) 371-6566

ROBERT GREENE STERNE
EDWARD J. KESSLER
JORGE A. GOLDSTEIN
SAMUEL L. FOX
DAVID K.S. CORNWELL
ROBERT W. ESMOND
TRACY-GENE G. DURKIN
MICHELE A. CIMBALA
MICHAEL B. RAY
ROBERT E. SOKOHL
ERIC K. STEFFE
MICHAEL O. LEE

JOHN M. COVERT*
LINDA E. ALCORN
RAZ E. FLESHNER
ROBERT C. MILLONIG
STEVEN R. LUDWIG
MICHAEL V. MESSINGER
JUDITH U. KIM*
KEITH KIND
TIMOTHY J. SHEA, JR.
DONALD R. MCPHAIL
PATRICK E. GARRETT
BARBARA A. PARVIS
MICHAEL A. RAHMAN*

STEPHEN G. WHITESIDE*
NOEL B. WHITLEY*
JEFFREY T. HELVEY*
RICHARD A. DUNNING, JR.
KIMBERLIN M. TOOHEY
RALPH P. ALBRECHT
HEIDI L. KRAUS*
JEFFREY R. KURIN*
CARL B. MASSEY, JR.*
RAYMOND MILLIEN*
PATRICK D. O'BRIEN*
BRIAN S. ROSENBLUM*

DONALD J. FEATHERSTONE**
LAWRENCE B. BUGAISKY**
KAREN R. MARKOWICZ**
GRANT E. REED**
VICTOR E. JOHNSON**
SERGE SIRA**

*BAR OTHER THAN D.C.
**REGISTERED PATENT AGENTS

WRITER'S DIRECT NUMBER

INTERNET ADDRESS

April 10, 1998

Box Patent Application

Assistant Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Non-Provisional Utility Patent Application under 37 C.F.R. § 1.53(b)
Appl. No. (to be assigned); filed (herewith)
For: **RNA Isolation Reagent and Methods**
Inventor: Domenica A. Simms
Our Ref: 0942.3840001/RWE

Sir:

The following documents are forwarded herewith for appropriate action by the U.S.
Patent and Trademark Office:

1. Utility Patent Application Transmittal (Form PTO/SB/05);
2. U.S. Utility Patent Application entitled:

RNA Isolation Reagent and Methods

and naming as inventor:

Domenica A. Simms

Assistant Commissioner for Patents
April 10, 1998
Page 2

the application comprising:


- 13 pages of description prior to the claims;
 - 4 pages of claims (claims 1-20); and
 - 1 page abstract;
3. Authorization to Treat a Reply As Incorporating An Extension of Time Under 37 C.F.R. § 1.136(a)(3) (in duplicate); and
 4. Two (2) return postcards.

It is respectfully requested that, of the two attached postcards, one be stamped with the filing date of these documents and returned to our courier, and the other, prepaid postcard, be stamped with the filing date and unofficial application number and returned as soon as possible.

This patent application is being submitted under 37 C.F.R. § 1.53(b) without Declaration and without filing fee.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert W. Esmond
Attorney for Applicant
Registration No. 32,893

RWE/dab
P:\USERS\DENISEB\0942\3841cov
Enclosures

Please type a sign(+) inside this box



PTO/SB/05 (2/98)

Approved for use through 09/30/2000 OMB 0651-0032
Patent and Trademark Office U S DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

UTILITY PATENT APPLICATION TRANSMITTAL (Only for new nonprovisional applications under 37 CFR § 1.53(b))	Attorney Docket No	0942.3840001/RWE
	First Named Inventor or Application Identifier	Domenica A Simms
	Title	RNA Isolation Reagent and Methods
	Express Mail Label No	

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents	ADDRESS TO Assistant Commissioner for Patents Box Patent Application Washington, DC 20231
--	--

1. ☐ * Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)
2. ☒ Specification [Total Pages]
(preferred arrangement set forth below)
- Descriptive title of the invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to Microfiche Appendix
- Background of the invention
- Brief Summary of the invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure
3. ☐ Drawing(s) (35 U.S.C. 113) [Total Sheets]
4. ☐ Oath or Declaration [Total Pages]
a. ☐ Newly executed (original or copy)
b. ☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation divisional with Box 17 completed) [Note Box 5 below]
i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b)
5. ☐ Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein
6. ☐ Microfiche Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
a. ☐ Computer Readable Copy
b. ☐ Paper Copy (identical to computer copy)
c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☐ *Small Entity Statement(s) ☐ Statement filed in prior application. Status still proper and desired
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☒ Other 37 CFR § 1.136(a)(3) Authorization
☐ Other
- *NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 CFR § 1.27). EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 CFR § 1.28)

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment

☐ Continuation ☐ Divisional ☐ Continuation-in-Part (CIP) of prior application No: ____/____

Prior application information Examiner _____ Group/Art Unit: _____


18. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label

(Insert Customer No. or Attach bar code label here)

or ☒ Correspondence address below

NAME	STERNE, KESSLER, GOLDSTEIN & FOX P I L C				
	Attorneys at Law				
ADDRESS	Suite 600, 1100 New York Avenue, N W				
CITY	Washington	STATE	DC	ZIP CODE	20005-3934
COUNTRY	USA	TELEPHONE	(202) 371-2600	FAX	(202) 371-2540

NAME (Print/Type)	Robert W Esmond	Registration No. (Attorney Agent)	32,893
SIGNATURE		Date	April 10, 1998

Burden Hour Statement: this form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

RNA Isolation Reagent and Methods

Background of the Invention

Field of the Invention

5 The present invention is in the field of molecular biology. The invention relates to improved methods, extraction reagents and kits for isolating RNA from eukaryotic cells, such as plant or animal cells.

Related Art

10 RNA isolation reagents and methods have been developed for isolating RNA, preferably cytoplasmic RNA and mRNA, from animal cells. These reagents and methods, when applied to the isolation of RNA from plant materials and plant cells, suffer from problems involving: the presence of Mg^{++} ions which degrade RNA; co-isolation of polysaccharides with RNA when strong chaotropic salts or ionic detergents are used; and the use of high salt concentrations requiring additional precipitation/redissolving steps. These methods give unsatisfactory results when applied to the isolation of RNA from plants.

15 U.S. Patent Numbers 5,346,994 and 4,843,155 disclose the use of extraction reagents having chaotropic salts (e.g., guanidinium isothiocyanate and ammonium isothiocyanate in high concentration (0.5-3M)), which completely disrupts cells and their nuclei, releasing RNA, DNA, proteins, membranous materials, and soluble polysaccharides into the extraction media. By virtue of the acidity and high salt concentration of the extraction media, the DNA precipitates out and is removed along with any insoluble cell debris during the centrifugation step.

20 Similar protocols are disclosed in Lewin, B.M., *Genes III*, John Wiley & Sons, publishers, New York, N.Y. (1990); Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second edition, Cold Spring Harbor

25

Laboratory, Cold Spring Harbor, NY (1989); and Ausubel et al., *Current Protocols in Molecular Biology*, Wiley Interscience, N.Y. (1987-1996).

5 The presence of chlorophyll and increased amounts of polysaccharides in plants provides additional problems for RNA isolation from such samples. In particular, the conventional use of chaotropic agents results in co-isolation of polysaccharides with the purified RNA. As plant cells have higher concentrations of polysaccharides, this problem is exacerbated by using known RNA isolation methods.

10 Furthermore, chlorophyll is broken down when plant cells are subjected to known RNA isolation methods and Mg^{++} ions are released from the chlorophyll. The Mg^{++} ions react with RNA and degrade it, reducing the yield and at least partially destroying the integrity of the RNA sequence.

15 Sambrook (*supra*, at sec. 7.6-7.9) discloses an alternative protocol for the isolation of cytoplasmic RNA from mammalian cells, which uses a non-disruptive RNA extraction reagent at physiological pH and salt concentration, instead of high concentrations of chaotropic salts. The extraction reagent contains an RNase inhibitor to protect the RNA during the isolation procedure and a nonionic detergent that solubilizes the cell membrane while leaving the nuclear membrane intact, to release cytoplasmic RNA. By not
20 disrupting the nucleus and other cell organelles, the cytoplasmic RNA in the extraction media is selectively extracted from the cell, and separated from cell debris by a centrifugation step. However, the Sambrook protocol suffers from the problem of requiring expensive RNase inhibitors and extensive sample handling to recover the purified mRNA. The presence of a cell wall was also a deterrent
25 from applying this technology to plant specimens.

Accordingly, improved methods and reagents are needed for RNA isolation from plants and plant or animal cells, which methods and reagents overcome one or more problems of known methods and reagents.

Summary of the Invention

The invention provides methods, extraction reagents and kits for RNA isolation from eukaryotic cells provided in a sample, where the use of at least a phenol, a chelator and a nonionic detergent replaces chaotropes and/or RNase inhibitors in the extraction reagent. These methods, reagents and kits provide superior results for isolation of cytoplasmic RNA or mRNA from eukaryotic cells, especially from plants, maintaining the integrity of the RNA without co-isolation of polysaccharides.

In a method of the present invention, an extraction reagent is used on fresh or frozen eukaryotic cells, or preferably frozen, powdered plant and animal samples. The RNA is localized in the aqueous phase after phase separation, and then precipitated with alcohol.

The process can comprise:

- (a) mixing the sample (or cell pellet) with the extraction reagent to form a mixture;
- (b) adding a haloalkane to the mixture and mixing;
- (c) separating the organic and aqueous phases by centrifugation or other known methods and transferring the aqueous phase; and
- (d) precipitating the cytoplasmic RNA from the aqueous phase obtained in step (c) with alcohol.

The process can optionally further comprise: (e) recovering the cytoplasmic RNA from the precipitate obtained in step (d). The process can also optionally further comprise: (f) isolating mRNA from the recovered cytoplasmic RNA (*e.g.*, as a precipitate) using any known method, such as by chromatography on oligo(dT)-cellulose (*see, e.g.*, Sambrook, *infra*, at §§ 7.26-7.29).

The extraction reagent preferably comprises:

- (a) at least one nonionic detergent (0.1-1.0% by volume);
- (b) at least one chelator (0.02-0.25 M);
- (c) at least one phenol (10%-60% by weight); and
- (d) at least one phenol solubilizer (15%-55% by volume).

The extraction reagent optionally further comprises:

- (e) at least one phenol stabilizer (0.05%-0.2% by weight);

The methods are useful for providing cytoplasmic or mRNA from cells contained in samples from eukaryotic organisms, with improved quantitative and/or qualitative yield over known methods, with RNA isolation from plants or plant cells preferred.

Another embodiment of the present invention relates to a kit comprising a carrier or receptacle being compartmentalized to receive and hold therein at least one container, wherein a first container contains at least one RNA reagent of the present invention, as described herein.

Other objects of the invention will be apparent to one of ordinary skill in the art from the following detailed description and examples relating to the present invention.

Detailed Description of the Preferred Embodiments

The invention is directed to methods and reagents using at least one of a phenol, a phenol stabilizer, a phenol solubilizer, a chelator and a nonionic detergent in the extraction reagent, in order to replace chaotropes and/or RNase inhibitors, and to provide enhanced isolation of intact cytoplasmic RNA from samples of eukaryotic organisms, tissues or cells.

In the present invention, subsequent sample handling is reduced substantially, as well as the material and labor costs for performing the RNA isolation. The use of a phenol, a chelator, a nonionic detergent, low salt concentrations, and no chaotropic agents improves the RNA isolation procedure, quantitatively and/or qualitatively.

The present invention provides several improvements over the related art, such as, but not limited to, at least one of: (a) the novel use of a chelator to protect the extracted RNA from degradation by Mg^{++} ions (*e.g.*, as present in animal cells, and as releasable from plant chlorophyll during the isolation process) in combination with phenol to protect the RNA from RNases; (b) the absence of

strong chaotropic agents from the RNA extraction media minimizes co-isolation of polysaccharides with the purified RNA; (c) the use of the low salt concentration in the RNA extraction medium, where (after addition of chloroform and phase separation) mRNA can be selected directly from the aqueous phase, while reducing or eliminating additional precipitation/redissolving steps.

The methods and reagents of the invention provide isolation of cytoplasmic RNA from eukaryotic organisms, such as, but not limited to, one or more of plants or plant materials or cells, animal cells or tissue, insects or insect cells, fungal hyphae or cells and other nucleated cells.

In a preferred embodiment, the eukaryotic sample (e.g., a plant sample) is preferably ground to a powder in liquid nitrogen, or by any other known method, where the sample remains frozen throughout the grinding procedure before RNA isolation. Alternatively, cell samples can be fresh or frozen but need not be ground into a powder. The invention thus provides direct isolation of cytoplasmic RNA or mRNA from eukaryotic cells.

RNA Extraction Reagents

In a preferred embodiment, the extraction reagent comprises:

- (a) at least one nonionic detergent (0.1-1.0% by volume) (e.g., tert-octylphenoxypoly(oxyethylene)ethanol (IGEPAL CA-630, Rhône Poulenc, France, 0.3-0.7%);
- (b) at least one chelator (0.02-0.25 M) (e.g., 0.05-0.5 M sodium citrate); and
- (c) at least one phenol (10%-60% by weight) (e.g., 20-40%); and
- (d) at least one phenol solubilizer (15%-55% by volume) (e.g., ethylene glycol, 22%).

The composition optionally further comprises:

- (e) at least one phenol stabilizer (0.05%-0.2% by weight) (e.g., hydroxyquinoline, 0.1%).

Nonionic Detergents. Suitable nonionic detergents include, but are not limited to, at least one selected from the group consisting of adducts of ethylene oxide and fatty alcohols, alkyl phenols, and fatty acid amides, N,N-bis(3-D-gluconamidopropyl)cholamides (BIGCHAP), decanoyl-N-methylglucamides, n-decyl α -D-glucopyranosides, n-decyl β -D-glucopyranosides, n-decyl β -D-maltopyranosides, deoxy-BIGCHAPs, digitonins, n-dodecyl β -D-glucopyranosides, n-dodecyl α -D-maltosides, n-dodecyl β -D-maltosides, heptanoyl-N-methylglucamides, n-heptyl β -D-glucopyranosides, N-heptyl β -D-thiogluconopyranosides, n-hexyl β -D-glucopyranosides, 1-monooleoyl-rac-glycerols, nonanoyl-N-methylglucamides, n-nonyl α -D-glucopyranosides, n-nonyl β -D-glucopyranosides, octanoyl-N-methylglucamides, n-octyl α -D-glucopyranosides, n-octyl β -D-glucopyranosides, octyl β -D-thiogalactopyranosides, octyl β -D-thiogluconopyranosides, polyoxyethylene esters, polyoxyethylene ethers, octylphenoxypoly(oxyethylene)ethanol (IGEPAL CA-360, Triton X-100), polyoxyethylenesorbitan esters (Tween 20), sorbitan esters, tergitols, n-tetradecyl β -D-maltosides, tritons, tyloxapol, and n-undecyl β -D-glucopyranosides. Tritons can include, but are not limited to, triton X-100 (t-octylphenoxypolyethoxyethanol); triton X-100, peroxide- and carbonyl-free; triton X-100, reduced; triton X-100, reduced, peroxide- and carbonyl-free; triton X-114, triton X-405, triton N-101, triton X-405, reduced; other tritons, such as but not limited to the following:


Non-ionic	Low-foam
N-42	CF-10
N-57	CF-21
N-60	CF-32 (95%)
X-15	CF-54
X-35	DF-12
X-45	DF-16
X-102	

Non-ionic	Low-foam
X-155	
X-165 (70%)	
X-207	
X-305 (70%)	
X-705-70 (70%)	
B-1956 (77%)	

Additional suitable nonionic detergents include triton CG-110, triton XL-80N, triton WR-1339 or tyloxapol, tert-octylphenoxy poly(oxyethylene) ethanol (*e.g.*, IGEPAL (Rhône-Poulenc, Paris, France)), and Nonidet P40 (octylphenoxy polyethoxy ethanol).

Chelators. Chelators include, but are not limited to: EDTAs, EGTA's, sodium citrates (citric acids), salicylic acids (and their salts), phthalic acids, 2,4-pentanediones, histidines, histidinol dihydrochlorides, 8-hydroxyquinolines, 8-hydroxyquinoline citrates, and *o*-hydroxyquinones.

Phenols. Any suitable phenolic compound can be used, *e.g.*, according to the following formula I:



where R_1 , R_2 , R_3 , R_4 , R_5 are each independently selected from H, alkyl, halo, *o*-alkyl, acyl and hydroxyl. Examples include, but are not limited to: phenol, *o*-cresol, *m*-cresol, *p*-cresol, resorcinol, β -resorcylaldehyde and the like.

Phenol Stabilizers. Phenol stabilizers include, but are not limited to: 8-hydroxyquinolines, 8-hydroxyquinoline citrates, 2,5,7,8-tetramethyl-2-(4',8',12'-

trimethyltridecyl)-6-chromanols, *p*-hydroxyquinones, *o*-hydroxyquinones, citric acids (and their salts), salicylic acids, ascorbic acids, *p*-phenylenediamines, *n*-propylgallates, and other known radical scavengers.

Phenol Solubilizers. Phenol solubilizers include, but not limited to: any alcohol miscible with phenol and water, *e.g.*, monoalcohols (such as, but not limited to: methyl alcohol, ethyl alcohol, propyl alcohol, and the like); diols (such as, but not limited to: ethylene glycol, propanediol, and the like); and, polyols (such as, but not limited to: glycerol, polyethylene glycol, polyvinyl alcohol, and the like).

The above compounds are commercially available, *e.g.*, from Sigma-Aldrich (St. Louis, MO).

See, e.g., Myers, *Surfactant Science and Technology*, VCH Publishers, Inc., New York (1992); Cutler, *supra*; Rosen, *Surfactants and Interfacial Phenomena*, Wiley, New York (1984); Schick *et al.* *Surfactant Science Series*, Vols. 1-22, Dekker, New York (1961-1987); Tadros, *Surfactants*, Academic Press, London (1984); which references are entirely incorporated herein by reference with regard to their teaching of detergents and/or surfactants.

RNA Recovery Process

An example of a process according to the present invention for providing RNA, includes, but is not limited to:

- (a) mixing the sample with the extraction reagent to form a mixture;
- (b) adding a haloalkane to the mixture;
- (c) separating the organic and aqueous phases; and
- (d) precipitating the cytoplasmic RNA from the aqueous phase obtained in step (c).

The process can optionally further comprise: (e) recovering the cytoplasmic RNA from the precipitate obtained in step (d). The process can also optionally further comprise: (f) isolating mRNA from the recovered cytoplasmic RNA precipitate

using any known method, such as by chromatography on oligo(dT)-cellulose (see, e.g., Sambrook, *infra*, at § 7.26-7.29).

5 In step (b) of the above method, the haloalkane added to the sample and extraction reagent mixture can be any haloalkane suitable for separating RNA from other cytoplasmic components. Such haloalkanes include, but are not limited to chloroform, methylene chloride (dichloromethane), 1-bromo-3-chloropropane, 2-bromo-1-chloropropane, bromoethane, 1-bromo-5-chloropentane, and bromotoluene.

10 In step (c) of the above method, the phases can be separated using any suitable method for separating RNA in an aqueous phase from other cytoplasmic components in the organic phase. Such separation methods include, but are not limited to centrifugation, filtration, vacuum filtration, or gravity.

15 In step (d) of the above method, the cytoplasmic RNA can be separated using any suitable method for precipitating RNA from the aqueous phase. Such separation methods include, but are not limited to using alcohol, polyethylene glycol, lithium chloride, or the like.

20 In step (e) of the above method, the cytoplasmic RNA can be recovered using any suitable method for recovering RNA from the precipitate. Such separation methods include, but are not limited to dissolving the RNA in water or in low salt buffer.

Having now generally described the invention, the same will be more readily understood through reference to the following example which is provided by way of illustration, and is not intended to be limiting of the present invention.

Example 1: Isolation of Plant RNA

Protocol for Isolation of Cytoplasmic RNA from a Plant Sample or Specimen

25 The plant specimen is ground into a powder in liquid nitrogen. The plant powder is stored and used frozen. 0.1 g of the frozen powdered plant is thoroughly mixed with 1 ml of the RNA extraction reagent of the invention and

is then let stand at room temperature for 5 minutes. 0.2 ml of chloroform per ml of the RNA extraction reagent is added to the mixture, and mixed thoroughly. The sample is centrifuged for 5 minutes at 12,000 x g at room temperature. (Larger quantities can be centrifuged for 30 minutes at 2600 x g or 6000 x g for 10 minutes at 4°C.)

The aqueous phase is transferred to an RNase-free tube. 0.5 ml of isopropanol per ml of RNA extraction reagent is added. The sample is mixed and let stand at room temperature for 10 minutes. The sample is centrifuged for 10 minutes at 12,000 x g at 4°C. (Larger quantities can be centrifuged for 30 minutes at 26000 x g or 6000 x g for 10 minutes at 4°C.) The supernate is decanted. The pellet is then washed with 1 ml of 75% ethanol per ml of RNA extraction reagent, centrifuged and any residual liquid is removed. RNase-free water is added to dissolve the RNA (50 µl of water for the 0.1 g sample).

Isolation of cytoplasmic RNA from cells grown in suspension. The cells are collected by centrifugation at 4°C for 5 minutes at 2000 g. The fresh or frozen cell pellet containing 1×10^7 cells is gently resuspended in 1 ml of RNA extraction reagent. The mixture is allowed to stand at room temperature for 5 minutes.

0.2 ml of chloroform is added per ml of RNA extraction reagent used., and mixed thoroughly. The sample is centrifuged for 5 minutes at 12,000 x g at room temperature. (Larger quantities can be centrifuged for 30 minutes at 2600 x g or 6000 x g for 10 minutes at 4°C.) The top, aqueous phase is transferred to an RNase-free tube, and 0.5 ml of isopropanol is added per ml of RNA extraction reagent. The supernatant is mixed and let stand at room temperature for 10 minutes.

The sample is centrifuged for 10 minutes at 12,000 x g at 4°C. (Larger quantities can be centrifuged for 30 minutes at 2600 x g or 6000 x g for 10 minutes at 4°C.) The supernate is decanted. It is then washed with 1 ml of 75% ethanol per ml of RNA extraction reagent, centrifuged and any residual liquid is removed. RNase-free water is added to dissolve the RNA (50 µl of water for the 1×10^7 cells sample).

Results using the above Protocol.

5 The following Table 1 shows results obtained using the above protocol,
as RNA yields.

Table 1

Sample	Method	Amount (g)	Ratio $A_{260/280}$	RNA (μg)
Tobacco leaves (soil grown plant)	RNA reagent	0.10	2.0	15
Tobacco leaves (soil grown plant)	RNA reagent	1.0	1.7	212
Tobacco leaves (soil grown plant)	RNA reagent	1.0	1.8	191
Tobacco leaves (soil grown plant)	Trizol	1.0	1.8	181
Tomato plant (culture)	RNA reagent	0.11	1.9	38
Tomato plant (culture)	RNA reagent	1.0	1.9	351
Tomato plant (culture)	Trizol	0.8	1.7	295
Blue spruce needles (dormant tree)	RNA reagent	0.11	1.5	16
Blue spruce needles (dormant tree)	RNA reagent	2.7	1.4	264
Blue spruce needles (dormant tree)	Trizol	2.7	0.6	12
Grass	RNA reagent	1.0	1.8	463
Grass	Trizol	1.0	1.8	160
Fungal hyphae, sense	RNA reagent	10^9 cells	1.8	274
Fungal hyphae, anti-sense	RNA reagent	10^9 cells	1.9	57
HeLa cells	RNA reagent	10^8 cells	1.8	2296

Having now fully described this invention it will be understood to those of ordinary skill in the art that the same can be performed within a wide and equivalent range of conditions, formulations and other parameters without affecting the scope of the invention or any embodiment thereof. All patents, patent applications and publications cited herein are entirely incorporated by reference herein.

5

10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995

What Is Claimed Is:

1. An aqueous RNA isolation reagent, comprising two or more components selected from the group consisting of

- (a) at least one nonionic detergent at a concentration of 0.1-1.0% (vol/vol);
- (b) at least one chelator at a concentration of 0.02-0.25 M; and
- (c) at least one phenol at a concentration of 10%-60% (wgt/vol); and
- (d) at least one phenol solubilizer at a concentration of 15%-55% (vol/vol).

2. An RNA isolation reagent according to claim 1, wherein said at least one nonionic detergent is present at a concentration of 0.5-0.8% (vol/vol).


3. An RNA isolation reagent according to claim 3, wherein said nonionic detergent comprises at least one detergent selected from the group consisting of an octylphenoxypoly(oxyethylene)ethanol, an N,N-bis(3-D-glucanamidopropyl)cholamide (BIGCHAP), an decanoyl-N-methylglucamide, an n-decyl α -D-glucopyranoside, an n-decyl β -D-glucopyranoside, an n-decyl β -D-maltopyranoside, a deoxy-BIGCHAP, a digitonin, an n-dodecyl β -D-glucopyranoside, an n-dodecyl α -D-maltoside, an n-dodecyl β -D-maltoside, a heptanoyl-N-methylglucamide, an n-heptyl β -D-glucopyranoside, an N-heptyl β -D-thioglucopyranoside, an n-hexyl β -D-glucopyranoside, a 1-monooleoyl-rac-glycerol, a nonanoyl-N-methylglucamide, an n-nonyl α -D-glucopyranoside, an n-nonyl β -D-glucopyranoside, an octanoyl-N-methylglucamide, an n-octyl α -D-glucopyranoside, an n-octyl β -D-glucopyranoside, an octyl β -D-thiogalactopyranoside, an octyl β -D-thioglucopyranoside, a polyoxyethylene ester, a polyoxyethylene ether, a polyoxyethylenesorbitan ester, Tween 20, a sorbitan ester, an n-tetradecyl β -D-maltoside, a triton, a tyloxaapol and an n-undecyl β -D-glucopyranoside.

4. An RNA extraction reagent according to claim 3, wherein said non-ionic detergent is a octylphenoxypoly(oxyethylene)ethanol.

5. An RNA extraction reagent according to claim 4, wherein said octylphenoxy(poly(oxyethylene))ethanol is present at a concentration of about 0.5% (vol/vol).

6. An RNA extraction reagent according to claim 1, wherein said chelator is selected from the group consisting of sodium citrate, EDTA, EGTA, sodium citrate, a citric acid, a salicylic acid or a salt thereof, a tergitol, a phthalic acid, a 2,4 pentanedione, a histidine, a histidinol dihydrochloride, an 8-hydroxyquinoline, an 8-hydroxyquinoline citrate and an *o*-hydroxyquinone.

7. An RNA extraction reagent according to claim 1, wherein said phenol is a compound according to formula I:



where R₁, R₂, R₃, R₄, R₅ are each independently selected from H, alkyl, o-alkyl, halo, acyl and hydroxyl.

8. An RNA extraction reagent according to claim 1, further comprising at least one phenol solubilizer at a concentration of 15%-55% (wgt/vol).

9. An RNA extraction reagent according to claim 8, wherein said phenol solubilizer is selected from the group consisting of a monoalcohol, a diol and a polyol.

5 10. An RNA extraction reagent according to claim 1, further comprising at least one phenol stabilizer at a concentration of 0.05%-0.2% (wgt/vol).

10 11. An RNA extraction reagent according to claim 10, wherein said phenol stabilizer is at least one selected from the group consisting of hydroxyquinoline, 8-hydroxyquinoline, 8-hydroxyquinoline citrate, 2,5,7,8-tetramethyl-2-(4',8',12'-trimethyltridecyl)-6-chroman-1-ol, *p*-hydroxyquinone, *o*-hydroxyquinone, citric acid or salt thereof, salicylic acid, ascorbic acid, *p*-phenylenediamine and *n*-propylgallate.

15 12. A kit for isolation of RNA, comprising at least one container, wherein a first container contains at least one RNA extraction reagent according to claim 1.

13. A method for providing cytoplasmic RNA from a sample comprising eukaryotic cells, said method comprising

- 20
- (a) mixing said sample containing said cells with an RNA extraction reagent according to claim 1 to form a mixture;
 - (b) adding a haloalkane to the mixture and mixing the resulting organic and aqueous phases;
 - (c) separating the organic and aqueous phases; and
 - (d) precipitating cytoplasmic RNA from the aqueous phase obtained in step (c).

14. A method according to claim 13, further comprising
(e) recovering the cytoplasmic RNA from the precipitate obtained in
step (d).

5

15. A method according to claim 14, further comprising
(f) isolating mRNA from said cytoplasmic RNA.

16. A method according to claim 14, wherein said sample is derived
from a plant or a plant material.

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

17. A method according to claim 13, wherein said cells are plant
cells.

18. A method according to claim 13, wherein said cells are animal
cells.

19. A method according to claim 17, wherein said animal cells are
mammalian cells.

15

20. A method according to claim 13, wherein said cells are insect
cells.

RNA Isolation Reagent and Methods

Abstract


The invention provides methods, extraction reagents and kits for RNA isolation from eukaryotic cells such as plant or animal cells, where a phenol, a phenol solubilizer, a chelator and a nonionic detergent are used in the extraction reagent to replace the need for chaotropes and/or RNase inhibitors.

5

a40-04.wpd

United States Patent & Trademark Office

Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

1. Application papers are not suitable for scanning and are not in compliance with 37 CFR 1.52 because:
 - ☐ All sheets must be the same size and either A4 (21 cm x 29.7 cm) or 8-1/2" x 11".
Pages _____ do not meet these requirements.
 - ☐ Papers are not flexible, strong, smooth, non-shiny, durable, and white.
 - ☐ Papers are not typewritten or mechanically printed in permanent ink on one side.
 - ☐ Papers contain improper margins. Each sheet must have a left margin of at least 2.5 cm (1") and top, bottom and right margins of at least 2.0 cm (3/4").
 - ☐ Papers contain hand lettering.
2. Drawings are not in compliance and were not scanned because:
 - ☐ The drawings or copy of drawings are not suitable for electronic reproduction.
 - ☐ All drawings sheets are not the same size. Pages must be either A4 (21 cm x 29.7 cm) or 8-1/2" x 11".
 - ☐ Each sheet must include a top and left margin of at least 2.5 cm (1"), a right margin of at least 1.5 cm (9/16") and a bottom margin of at least 1.0 cm (3/8").
3. Page(s) _____ are not of sufficient clarity, contrast and quality for electronic reproduction.
4. Page(s) _____ are missing.
5. OTHER: NO DECLARATION OF Drawing